(CCJ) Cameco - Ratings and Ratios
Uranium, Fuel Services, Reactor Technology, Components, Spare Parts
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 0.20% |
| Yield on Cost 5y | 1.26% |
| Yield CAGR 5y | 28.54% |
| Payout Consistency | 94.4% |
| Payout Ratio | 12.9% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 49.1% |
| Value at Risk 5%th | 76.5% |
| Relative Tail Risk | -5.32% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.70 |
| Alpha | 91.51 |
| CAGR/Max DD | 1.60 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.363 |
| Beta | 1.215 |
| Beta Downside | 1.122 |
| Drawdowns 3y | |
|---|---|
| Max DD | 40.01% |
| Mean DD | 9.88% |
| Median DD | 7.00% |
Description: CCJ Cameco December 03, 2025
Cameco Corp (NYSE:CCJ) is a vertically integrated uranium producer headquartered in Saskatoon, Canada. It operates three distinct segments: Uranium (exploration, mining, milling, and sales of U₃O₈ concentrate), Fuel Services (conversion, enrichment, and fabrication of nuclear fuel), and Westinghouse (design, OEM, and aftermarket services for commercial nuclear reactors). Its customer base spans nuclear utilities across the Americas, Europe, and Asia.
As of 2023, Cameco generated roughly 7.2 million lb of U₃O₈, with an average cash cost of about $30 per lb, positioning it among the lowest-cost producers globally. The company’s net debt stood at ≈ $1.5 billion, yielding a net-debt/EBITDA ratio of ~ 1.2×, which suggests moderate leverage relative to peers. Spot uranium prices have hovered near $55 / lb (2024-Q1), while long-term contract prices remain in the $65-$70 / lb band, creating a price-spread tailwind for cash flow.
The uranium market is currently driven by three macro forces: (1) a tightening supply outlook as legacy mines curtail output, (2) policy-driven nuclear expansion-particularly in China, India, and the United States-targeting an estimated + 30 GW of new capacity by 2035, and (3) heightened geopolitical risk that favours domestic supply chains for strategic materials. Assuming uranium demand grows at the sector-wide consensus rate of 2-3 % annually, Cameco’s low-cost profile could translate into a 10-15 % upside in earnings under a modest price recovery scenario; however, this projection is highly sensitive to spot-price volatility and the pace of new reactor construction.
For a deeper, data-driven look at Cameco’s valuation scenarios and sensitivity analyses, the ValueRay platform provides a transparent, up-to-date toolkit worth exploring.
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income (526.0m TTM) > 0 and > 6% of Revenue (6% = 207.9m TTM) |
| FCFTA 0.10 (>2.0%) and ΔFCFTA 6.83pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 36.28% (prev 35.41%; Δ 0.87pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.13 (>3.0%) and CFO 1.26b > Net Income 526.0m (YES >=105%, WARN >=100%) |
| Net Debt (228.5m) to EBITDA (1.07b) ratio: 0.21 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.99 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (435.4m) change vs 12m ago -0.02% (target <= -2.0% for YES) |
| Gross Margin 29.05% (prev 23.81%; Δ 5.24pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 36.41% (prev 30.11%; Δ 6.31pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 9.54 (EBITDA TTM 1.07b / Interest Expense TTM 78.0m) >= 6 (WARN >= 3) |
Altman Z'' 4.87
| (A) 0.13 = (Total Current Assets 1.89b - Total Current Liabilities 631.4m) / Total Assets 9.74b |
| (B) 0.36 = Retained Earnings (Balance) 3.49b / Total Assets 9.74b |
| (C) 0.08 = EBIT TTM 744.0m / Avg Total Assets 9.51b |
| (D) 2.22 = Book Value of Equity 6.57b / Total Liabilities 2.96b |
| Total Rating: 4.87 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 68.36
| 1. Piotroski 8.0pt |
| 2. FCF Yield 1.51% |
| 3. FCF Margin 28.07% |
| 4. Debt/Equity 0.15 |
| 5. Debt/Ebitda 0.21 |
| 6. ROIC - WACC (= -3.75)% |
| 7. RoE 7.98% |
| 8. Rev. Trend 73.46% |
| 9. EPS Trend 22.75% |
What is the price of CCJ shares?
Over the past week, the price has changed by +9.60%, over one month by +20.00%, over three months by +19.37% and over the past year by +125.42%.
Is CCJ a buy, sell or hold?
- Strong Buy: 10
- Buy: 9
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the CCJ price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 110.9 | 1% |
| Analysts Target Price | 110.9 | 1% |
| ValueRay Target Price | 173 | 57.5% |
CCJ Fundamental Data Overview January 10, 2026
P/E Trailing = 121.5632
P/E Forward = 75.7576
P/S = 13.3308
P/B = 9.2219
P/EG = 3.33
Beta = 1.217
Revenue TTM = 3.46b CAD
EBIT TTM = 744.0m CAD
EBITDA TTM = 1.07b CAD
Long Term Debt = 996.2m CAD (from longTermDebt, last quarter)
Short Term Debt = 289.2m CAD (from shortTermDebt, last fiscal year)
Debt = 1.01b CAD (from shortLongTermDebtTotal, last quarter)
Net Debt = 228.5m CAD (from netDebt column, last quarter)
Enterprise Value = 64.35b CAD (64.13b + Debt 1.01b - CCE 778.7m)
Interest Coverage Ratio = 9.54 (Ebit TTM 744.0m / Interest Expense TTM 78.0m)
EV/FCF = 66.17x (Enterprise Value 64.35b / FCF TTM 972.5m)
FCF Yield = 1.51% (FCF TTM 972.5m / Enterprise Value 64.35b)
FCF Margin = 28.07% (FCF TTM 972.5m / Revenue TTM 3.46b)
Net Margin = 15.18% (Net Income TTM 526.0m / Revenue TTM 3.46b)
Gross Margin = 29.05% ((Revenue TTM 3.46b - Cost of Revenue TTM 2.46b) / Revenue TTM)
Gross Margin QoQ = 37.32% (prev 29.31%)
Tobins Q-Ratio = 6.61 (Enterprise Value 64.35b / Total Assets 9.74b)
Interest Expense / Debt = 1.76% (Interest Expense 17.8m / Debt 1.01b)
Taxrate = 33.06% (84.9m / 256.7m)
NOPAT = 498.0m (EBIT 744.0m * (1 - 33.06%))
Current Ratio = 2.99 (Total Current Assets 1.89b / Total Current Liabilities 631.4m)
Debt / Equity = 0.15 (Debt 1.01b / totalStockholderEquity, last quarter 6.78b)
Debt / EBITDA = 0.21 (Net Debt 228.5m / EBITDA 1.07b)
Debt / FCF = 0.23 (Net Debt 228.5m / FCF TTM 972.5m)
Total Stockholder Equity = 6.59b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.53% (Net Income 526.0m / Total Assets 9.74b)
RoE = 7.98% (Net Income TTM 526.0m / Total Stockholder Equity 6.59b)
RoCE = 9.80% (EBIT 744.0m / Capital Employed (Equity 6.59b + L.T.Debt 996.2m))
RoIC = 6.50% (NOPAT 498.0m / Invested Capital 7.66b)
WACC = 10.25% (E(64.13b)/V(65.13b) * Re(10.39%) + D(1.01b)/V(65.13b) * Rd(1.76%) * (1-Tc(0.33)))
Discount Rate = 10.39% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.14%
[DCF Debug] Terminal Value 74.32% ; FCFF base≈700.8m ; Y1≈864.5m ; Y5≈1.47b
Fair Price DCF = 38.60 (EV 17.04b - Net Debt 228.5m = Equity 16.81b / Shares 435.4m; r=10.25% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 22.75 | EPS CAGR: -23.29% | SUE: -1.62 | # QB: 0
Revenue Correlation: 73.46 | Revenue CAGR: 7.75% | SUE: -0.58 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.39 | Chg30d=+0.017 | Revisions Net=-1 | Analysts=6
EPS next Year (2026-12-31): EPS=1.97 | Chg30d=+0.005 | Revisions Net=+2 | Growth EPS=+41.8% | Growth Revenue=+8.3%
Additional Sources for CCJ Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle